A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

Фаза 3 Завершено NCT05218655

Кратко

The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan. The study will continue until vatiquinone becomes commercially available or the program is terminated.

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Baseline (Day 1) up to 30 days after last dose of study drug (956 days) · Participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
• Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
• Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
• Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
• A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
• Maintenance TMS in Treatment Resistant Depression — Austin Messner

Все исследования